COVID-19 and COPD

Leung, Janice M.; Niikura, Masahiro; Yang, Cheng Wei Tony; Sin, Don D.

doi:10.1183/13993003.02108-2020

Cited by 278 publications

(289 citation statements)

References 104 publications

Supporting

Mentioning

222

Contrasting

Unclassified

Order By: Relevance

“…To verify whether TRIB3 expression is also decreased in the lungs of patients with comorbidities at high risk of developing severe COVID-19 such as asthma [ 27 ] and chronic obstructive pulmonary disease (COPD) [ 28 ], data of available studies were downloaded from public Gene Expression Omnibus (GEO) datasets (GSE158752, GSE85567 and GSE57148). Differential gene expression analysis was performed using the BioJupies platform by comparing each group of patients with asthma or COPD with their respective control group: 98 COPD vs. 91 controls, 57 Asthma vs. 28 controls, and 50 asthma vs. 17 controls.…”

Section: Methodsmentioning

confidence: 99%

Prediction of SARS-CoV Interaction with Host Proteins during Lung Aging Reveals a Potential Role for TRIB3 in COVID-19

Moraes¹,

Paiva²,

Cury³

et al. 2021

Aging and disease

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Prediction of SARS-CoV Interaction with Host Proteins during Lung Aging Reveals a Potential Role for TRIB3 in COVID-19

Moraes¹,

Paiva²,

Cury³

et al. 2021

Aging and disease

View full text Add to dashboard Cite

“…COPD (Chronic obstructive pulmonary disease) patients are very much susceptible to severe pneumonia upon infection with SARS-CoV-2 owing to enhanced expression of ACE2 receptor in the respiratory airways. The common respiratory medications given to COPD patients include inhaled and systemic corticosteroids, long-acting β 2 -agonists, and muscarinic antagonists [ 81 ]. But whether these medications mitigates or exacerbates COVID-19 infections remains obscure till date.…”

Section: Comorbidity Treatment Regimes For Covid-19 Patientsmentioning

confidence: 99%

Therapeutics and Vaccines: Strengthening Our Fight Against the Global Pandemic COVID-19

et al. 2021

View full text Add to dashboard Cite

The newly identified 2019 novel coronavirus (SARS-CoV-2) has become a public health concern globally posing a significant threat to human health and economy and creating an unprecedented crisis in all spheres of the global life. Emergence of new genotypes of SARS-CoV during the last few years has pointed out the limited efficacy of available vaccines and antivirals, constraining the global response to the COVID-19 outburst to largely monitoring/containment. There is high priority for treatment regimes and new potential therapeutic and vaccine strategies. Several candidates have shown promising outcomes in various in vitro and in vivo models. In addition, clinical trials are in progress to test conceivable therapies showing promising outcomes in various in vivo studies. Unfortunately, very little information is available in the scientific scope which offers details to the diverse strategies being targeted to fight the pandemic, particularly with respect to the molecular targets. This review article summarizes and highlights the ongoing advances and approaches that are being carried out across the globe in designing vaccines and novel therapeutics, with particular reference to the previous knowledge gained from other viral infections like with the earlier SARS and MERS-CoV. A detailed knowledge may pave the way to combat this pandemic COVID-19 as well as prevent similar deadly epidemics in future.

show abstract

“…Indeed, through high-sensitivity RNA in situ mapping technology, it has been shown that the highest ACE2 expression is detecting in the nose with a decreased expression all through the lower respiratory tract, this observation is paralleled by an outstanding gradient of SARS-CoV-2 infection in proximal (high) versus distal (low) pulmonary epithelial cultures [ 42 ]. Current smoking is associated with increased expression of gene for ACE2, and TMPRSS2 [ 43 , 44 , 45 , 46 ]. It has been shown that airway epithelial cell expression of CHRNA7, encoding α7-nAChR, is significantly correlated with the expression of ACE2 with a trend towards higher expression in current smokers as compared with former and never smokers [ 36 ].…”

Section: Introductionmentioning

confidence: 99%

Nicotine Changes Airway Epithelial Phenotype and May Increase the SARS-COV-2 Infection Severity

Lupacchini

Maggi

Tomino³

et al. 2020

Molecules

View full text Add to dashboard Cite

(1) Background: Nicotine is implicated in the SARS-COV-2 infection through activation of the α7-nAChR and over-expression of ACE2. Our objective was to clarify the role of nicotine in SARS-CoV-2 infection exploring its molecular and cellular activity. (2) Methods: HBEpC or si-mRNA-α7-HBEpC were treated for 1 h, 48 h or continuously with 10−7 M nicotine, a concentration mimicking human exposure to a cigarette. Cell viability and proliferation were evaluated by trypan blue dye exclusion and cell counting, migration by cell migration assay, senescence by SA-β-Gal activity, and anchorage-independent growth by cloning in soft agar. Expression of Ki67, p53/phospho-p53, VEGF, EGFR/pEGFR, phospho-p38, intracellular Ca2+, ATP and EMT were evaluated by ELISA and/or Western blotting. (3) Results: nicotine induced through α7-nAChR (i) increase in cell viability, (ii) cell proliferation, (iii) Ki67 over-expression, (iv) phospho-p38 up-regulation, (v) EGFR/pEGFR over-expression, (vi) increase in basal Ca2+ concentration, (vii) reduction of ATP production, (viii) decreased level of p53/phospho-p53, (ix) delayed senescence, (x) VEGF increase, (xi) EMT and consequent (xii) enhanced migration, and (xiii) ability to grow independently of the substrate. (4) Conclusions: Based on our results and on evidence showing that nicotine potentiates viral infection, it is likely that nicotine is involved in SARS-CoV-2 infection and severity.

show abstract

COVID-19 and COPD

Abstract: ERSpublications COPD patients have increased risk of severe pneumonia and poor outcomes when they develop COVID-19. This may be related to poor underlying lung reserves or increased expression of ACE-2 receptor in small airways.

Cited by 278 publications

References 104 publications

Prediction of SARS-CoV Interaction with Host Proteins during Lung Aging Reveals a Potential Role for TRIB3 in COVID-19

Prediction of SARS-CoV Interaction with Host Proteins during Lung Aging Reveals a Potential Role for TRIB3 in COVID-19

Therapeutics and Vaccines: Strengthening Our Fight Against the Global Pandemic COVID-19

Nicotine Changes Airway Epithelial Phenotype and May Increase the SARS-COV-2 Infection Severity

Contact Info

Product

Resources

About